“Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

“Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA) : Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”. / Meyer, Anna S.P.; Johansson, Per I.; Kjaergaard, Jesper; Frydland, Martin; Meyer, Martin A.S.; Henriksen, Hanne Hee; Thomsen, Jakob H.; Wiberg, Sebastian C.; Hassager, Christian; Ostrowski, Sisse R.

I: American Heart Journal, Bind 219, 2020, s. 9-20.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Meyer, ASP, Johansson, PI, Kjaergaard, J, Frydland, M, Meyer, MAS, Henriksen, HH, Thomsen, JH, Wiberg, SC, Hassager, C & Ostrowski, SR 2020, '“Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”', American Heart Journal, bind 219, s. 9-20. https://doi.org/10.1016/j.ahj.2019.10.002

APA

Meyer, A. S. P., Johansson, P. I., Kjaergaard, J., Frydland, M., Meyer, M. A. S., Henriksen, H. H., Thomsen, J. H., Wiberg, S. C., Hassager, C., & Ostrowski, S. R. (2020). “Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”. American Heart Journal, 219, 9-20. https://doi.org/10.1016/j.ahj.2019.10.002

Vancouver

Meyer ASP, Johansson PI, Kjaergaard J, Frydland M, Meyer MAS, Henriksen HH o.a. “Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”. American Heart Journal. 2020;219:9-20. https://doi.org/10.1016/j.ahj.2019.10.002

Author

Meyer, Anna S.P. ; Johansson, Per I. ; Kjaergaard, Jesper ; Frydland, Martin ; Meyer, Martin A.S. ; Henriksen, Hanne Hee ; Thomsen, Jakob H. ; Wiberg, Sebastian C. ; Hassager, Christian ; Ostrowski, Sisse R. / “Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA) : Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”. I: American Heart Journal. 2020 ; Bind 219. s. 9-20.

Bibtex

@article{726d140a76b84481a31b01daf7bc64e7,
title = "“Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”",
abstract = "Objective: An increasingly recognized prognostic factor for out-of-hospital-cardiac-arrest (OHCA) patients is the ischemia-reperfusion injury after restored blood circulation. Endothelial injury is common in patients resuscitated from cardiac arrest and is associated with poor outcome. This study was designed to investigate if iloprost infusion, a prostacyclin analogue, reduces endothelial damage in OHCA patients. Methods: 50 patients were randomized in a placebo controlled double-blinded trial and allocated 1:2 to 48-hours iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Endothelial biomarkers (soluble thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), vascular endothelial cadherine (VEcad), nucleosomes) and sympathoadrenal activation (epinephrine/norepinephrine) from baseline to 48 and 96-hours were evaluated. Results: Iloprost infusion did not influence endothelial biomarkers by the 48-hour endpoint. A rebound effect was observed with higher biomarker plasma values in the iloprost group (sTM p=0.02; Syndecan p=0.004; nucleosomes p<0.001; VEcad p<0.03) after 96-hours. There was a significant difference in 180-day mortality in favor of placebo. There was no difference regarding total adverse events between groups (p=0.73). Two patients were withdrawn in the iloprost group due to hypotension. Conclusions: The administration of low-dose iloprost (1ng/kg/min) to OHCA patients did not significantly influence endothelial biomarkers as measured by the 48- hour endpoint. A rebound effect was however observed in the 96-hour statistical model, with increasing endothelial biomarker levels after cessation of the iloprost-infusion.",
author = "Meyer, {Anna S.P.} and Johansson, {Per I.} and Jesper Kjaergaard and Martin Frydland and Meyer, {Martin A.S.} and Henriksen, {Hanne Hee} and Thomsen, {Jakob H.} and Wiberg, {Sebastian C.} and Christian Hassager and Ostrowski, {Sisse R.}",
year = "2020",
doi = "10.1016/j.ahj.2019.10.002",
language = "English",
volume = "219",
pages = "9--20",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

RIS

TY - JOUR

T1 - “Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA)

T2 - Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”

AU - Meyer, Anna S.P.

AU - Johansson, Per I.

AU - Kjaergaard, Jesper

AU - Frydland, Martin

AU - Meyer, Martin A.S.

AU - Henriksen, Hanne Hee

AU - Thomsen, Jakob H.

AU - Wiberg, Sebastian C.

AU - Hassager, Christian

AU - Ostrowski, Sisse R.

PY - 2020

Y1 - 2020

N2 - Objective: An increasingly recognized prognostic factor for out-of-hospital-cardiac-arrest (OHCA) patients is the ischemia-reperfusion injury after restored blood circulation. Endothelial injury is common in patients resuscitated from cardiac arrest and is associated with poor outcome. This study was designed to investigate if iloprost infusion, a prostacyclin analogue, reduces endothelial damage in OHCA patients. Methods: 50 patients were randomized in a placebo controlled double-blinded trial and allocated 1:2 to 48-hours iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Endothelial biomarkers (soluble thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), vascular endothelial cadherine (VEcad), nucleosomes) and sympathoadrenal activation (epinephrine/norepinephrine) from baseline to 48 and 96-hours were evaluated. Results: Iloprost infusion did not influence endothelial biomarkers by the 48-hour endpoint. A rebound effect was observed with higher biomarker plasma values in the iloprost group (sTM p=0.02; Syndecan p=0.004; nucleosomes p<0.001; VEcad p<0.03) after 96-hours. There was a significant difference in 180-day mortality in favor of placebo. There was no difference regarding total adverse events between groups (p=0.73). Two patients were withdrawn in the iloprost group due to hypotension. Conclusions: The administration of low-dose iloprost (1ng/kg/min) to OHCA patients did not significantly influence endothelial biomarkers as measured by the 48- hour endpoint. A rebound effect was however observed in the 96-hour statistical model, with increasing endothelial biomarker levels after cessation of the iloprost-infusion.

AB - Objective: An increasingly recognized prognostic factor for out-of-hospital-cardiac-arrest (OHCA) patients is the ischemia-reperfusion injury after restored blood circulation. Endothelial injury is common in patients resuscitated from cardiac arrest and is associated with poor outcome. This study was designed to investigate if iloprost infusion, a prostacyclin analogue, reduces endothelial damage in OHCA patients. Methods: 50 patients were randomized in a placebo controlled double-blinded trial and allocated 1:2 to 48-hours iloprost infusion, (1 ng/kg/min) or placebo (saline infusion). Endothelial biomarkers (soluble thrombomodulin (sTM), sE-selectin, syndecan-1, soluble vascular endothelial growth factor (sVEGF), vascular endothelial cadherine (VEcad), nucleosomes) and sympathoadrenal activation (epinephrine/norepinephrine) from baseline to 48 and 96-hours were evaluated. Results: Iloprost infusion did not influence endothelial biomarkers by the 48-hour endpoint. A rebound effect was observed with higher biomarker plasma values in the iloprost group (sTM p=0.02; Syndecan p=0.004; nucleosomes p<0.001; VEcad p<0.03) after 96-hours. There was a significant difference in 180-day mortality in favor of placebo. There was no difference regarding total adverse events between groups (p=0.73). Two patients were withdrawn in the iloprost group due to hypotension. Conclusions: The administration of low-dose iloprost (1ng/kg/min) to OHCA patients did not significantly influence endothelial biomarkers as measured by the 48- hour endpoint. A rebound effect was however observed in the 96-hour statistical model, with increasing endothelial biomarker levels after cessation of the iloprost-infusion.

U2 - 10.1016/j.ahj.2019.10.002

DO - 10.1016/j.ahj.2019.10.002

M3 - Journal article

C2 - 31710844

AN - SCOPUS:85074638943

VL - 219

SP - 9

EP - 20

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

ID: 260197111